Phase 3 trial in 4055 African infants, stopped early after an interim analysis: parenteral TV P2-VP8 was inferior to oral ROTARIX against severe rotavirus gastroenteritis (4.51% vs 2.57%; relative efficacy −77.68%), though safe and immunogenic.
RCTn = 4,055
Tewari et al. Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus subunit vaccine candidate (TV P2-VP8) in healthy Ghanaian, Malawian, and Zambian infants